Disease · MONDO_0004994

cardiomyopathy

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. cardiomyopathy. Diseases, record MONDO_0004994. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0004994

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: cardiomyopathy; Open Targets
Open Targets ID: MONDO_0004994; Open Targets
Other names: CARDIOMYOPATH IN OTH DIS, CARDIOMYOPATHIES SECOND, Cardiomyopathies, Cardiomyopathies, Primary, Cardiomyopathies, Secondary, Cardiomyopathy (disorder), Cardiomyopathy NOS, Cardiomyopathy NOS (disorder), Cardiomyopathy in other diseases classified elsewhere, Cardiomyopathy, Primary, Cardiomyopathy, Secondary, Other primary cardiomyopathies, Other primary cardiomyopathies (disorder), Other primary cardiomyopathy NOS, Other primary cardiomyopathy NOS (disorder), PRIM CARDIOMYOPATHY NEC, Primary Cardiomyopathies, Primary Cardiomyopathy, Secondary Cardiomyopathies, Secondary Cardiomyopathy, [X]Cardiomyopathy in other diseases classified elsewhere, [X]Cardiomyopathy in other diseases classified elsewhere (disorder); Open Targets
Disease Ontology: DOID:0050700; Disease Ontology
MeSH: D009202; MeSH
NCI Thesaurus: C34830; NCI Thesaurus
Orphanet: ORPHA:167848; Orphanet
Highest stage of its drugs: Approval, for 4 of its 36 drugs, from DailyMed and FDA; Open Targets

Drugs36

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
TAFAMIDIS	CHEMBL2103837	Small molecule	Approval	DailyMed and FDA	3	0	0	Drugs and targets
DEXRAZOXANE HYDROCHLORIDE	CHEMBL1200778	Small molecule	Approval	DailyMed	2	0	0	Drugs and targets
TAFAMIDIS MEGLUMINE	CHEMBL2105675	Small molecule	Approval	FDA	2	0	0	Drugs and targets
ACORAMIDIS HYDROCHLORIDE	CHEMBL4650226	Small molecule	Approval	FDA	1	0	0	Drugs and targets
EPLERENONE	CHEMBL1095097	Small molecule	Phase 3	ClinicalTrials.gov	2	2	2	Drugs and targets
AZATHIOPRINE	CHEMBL1542	Small molecule	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
MELATONIN	CHEMBL45	Small molecule	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
PREDNISONE	CHEMBL635	Small molecule	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
SPIRONOLACTONE	CHEMBL1393	Small molecule	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
REVUSIRAN	CHEMBL4594492	Oligonucleotide	Phase 3	TTD	1	0	0	Drugs and targets

1 to 10 of 36

See all 36 drugs

Targets39

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
TTR	Transthyretin	5	Transthyretin mRNA RNAi inhibitor; Transthyretin stabiliser	Approval	https://conductscience.org/library/genes/7276	Drugs and targets
NR3C1	Glucocorticoid receptor	2	Glucocorticoid receptor agonist	Phase 3	https://conductscience.org/library/genes/2908	Drugs and targets
NR3C2	Mineralocorticoid receptor	2	Mineralocorticoid receptor antagonist	Phase 3	https://conductscience.org/library/genes/4306	Drugs and targets
SLC5A2	Sodium/glucose cotransporter 2	2	Sodium/glucose cotransporter 2 inhibitor	Phase 1	https://conductscience.org/library/genes/6524	Drugs and targets
ACE	Angiotensin-converting enzyme	1	Angiotensin-converting enzyme inhibitor	Unknown	https://conductscience.org/library/genes/1636	Drugs and targets
AGTR1	Type-1 angiotensin II receptor	1	Type-1 angiotensin II receptor antagonist	Unknown	https://conductscience.org/library/genes/185	Drugs and targets
IMPDH1	Inosine-5'-monophosphate dehydrogenase (IMPDH)	1	Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitor	Phase 2/3	https://conductscience.org/library/genes/3614	Drugs and targets
IMPDH2	Inosine-5'-monophosphate dehydrogenase (IMPDH)	1	Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitor	Phase 2/3	https://conductscience.org/library/genes/3615	Drugs and targets
MAS1	Proto-oncogene Mas	1	Proto-oncogene Mas agonist	Phase 2	https://conductscience.org/library/genes/4142	Drugs and targets
MMP1	Interstitial collagenase	1	Matrix metalloproteinase-1 inhibitor	Phase 1/2	https://conductscience.org/library/genes/4312	Drugs and targets

1 to 10 of 39

See all 39 targets

Trials22

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT02214160	Long-Chain Fatty Acid Oxidation Disorders (LC-FAOD) Extension Study for Subjects Previously Enrolled in Triheptanoin Studies	Phase 2	94	2021-12-08	Carnitine Palmitoyltransferase (CPT I or CPT II) Deficiency, Very Long Chain Acyl-CoA Dehydrogenase (VLCAD) Deficiency, Long-chain 3-hydroxy-acyl-CoA Dehydrogenase (LCHAD) Deficiency, Trifunctional Protein (TFP) Deficiency, Carnitine-acylcarnitine Translocase (CACT) Deficiency	TRIHEPTANOIN	Its record names the disease	ClinicalTrials.gov
NCT02354352	Therapeutic Potential for Aldosterone Inhibition in Duchenne Muscular Dystrophy	Phase 3	52	2019-09-24	Duchenne Muscular Dystrophy	EPLERENONE, SPIRONOLACTONE	Its record names the disease	ClinicalTrials.gov
NCT03340675	Oral Ifetroban in Subjects With Duchenne Muscular Dystrophy	Phase 2	46	2026-01-26	Duchenne Muscular Dystrophy Cardiomyopathy, Cardiomyopathy, Dilated	IFETROBAN	Its record names the disease	ClinicalTrials.gov
NCT01521546	Eplerenone for Subclinical Cardiomyopathy in Duchenne Muscular Dystrophy	Not applicable	42	2015-05-27	Duchenne Muscular Dystrophy	EPLERENONE	Its record names the disease	ClinicalTrials.gov
NCT01855360	Doxycycline and TUDCA in Patients With Transthyretin Amyloid Cardiomyopathy	Phase 1/2	40	2020-12-04	Amyloidosis; Heart (Manifestation), Senile Cardiac Amyloidosis	DOXYCYCLINE, TAURURSODIOL	Its record names the disease	ClinicalTrials.gov
NCT01982695	Cardiomyopathy in DMD: Lisinopril vs. Losartan	Not applicable	23	2017-03-21	Duchenne Muscular Dystrophy (DMD), Cardiomyopathy	LISINOPRIL, LOSARTAN	Its record names the disease	ClinicalTrials.gov
NCT01168908	Revatio for Heart Disease in Duchenne Muscular Dystrophy and Becker Muscular Dystrophy	Phase 2	20	2018-03-21	Duchenne Muscular Dystrophy, Becker Muscular Dystrophy	SILDENAFIL	Its record names the disease	ClinicalTrials.gov
NCT02964377	Plus Epicatechin Duchenne Muscular Dystrophy in Non-ambulatory Adolescents	Phase 1/2	15	2021-12-21	Duchenne Muscular Dystrophy	(+)-EPICATECHIN, (-)-EPICATECHIN	Its record names the disease	ClinicalTrials.gov
NCT00691470	Comparison of ATI-5923, a Novel Vitamin K Antagonist, With Warfarin in Patients Requiring Chronic Anticoagulation	Phase 2/3	600		Atrial Fibrillation, Atrial Flutter, Venous Thromboembolic Disease, Myocardial Infarction, Cardiomyopathy	TECARFARIN SODIUM, WARFARIN	Its record names the disease	ClinicalTrials.gov
NCT00970892	VKORC1 and CYP2C9 Gene Polymorphisms and Warfarin Management		500		Atrial Fibrillation, Cardiac Thrombus, Deep Vein Thrombosis, Pulmonary Embolism, Heart Valve Replacement (Mechanical or Biological With AF), Cardiomyopathy (Ischemic or Dilated), Peripheral Vascular Disease	WARFARIN	Its record names the disease	ClinicalTrials.gov

1 to 10 of 22

See all 22 trials

Comparisons in its trials6

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Eplerenone vs Spironolactone: deaths from any cause	2 of 26	0 of 26	52	NCT02354352	Trial comparisons
Eplerenone vs Spironolactone: serious adverse events	3 of 26	2 of 26	52	NCT02354352	Trial comparisons
Eplerenone vs Placebo: serious adverse events	0 of 20	1 of 22	42	NCT01521546	Trial comparisons
Revatio (Sildenafil) vs Placebo: deaths from any cause	1 of 18	0 of 10	28	NCT01168908	Trial comparisons
Revatio (Sildenafil) vs Placebo: serious adverse events	5 of 18	1 of 10	28	NCT01168908	Trial comparisons
Lisinopril vs Losartan: serious adverse events	0 of 12	0 of 10	22	NCT01982695	Trial comparisons

Papers from its trials8

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
22463839	RESULT	1	PubMed
40781621	DERIVED	1	PubMed
34048282	DERIVED	1	PubMed
31549577	DERIVED	1	PubMed
28219442	DERIVED	1	PubMed
25554404	DERIVED	1	PubMed
25042693	DERIVED	1	PubMed
24459612	DERIVED	1	PubMed

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0004994

GET https://conductscience.org/api/diseases/v1/MONDO_0004994/drugs?page=2

API reference For AI assistants